Results 181 to 190 of about 17,756 (247)

Plasmacytoid dendritic cells in systemic and cutaneous lupus erythematosus: an evolving understanding. [PDF]

Front Immunol
Werth VP, Rönnblom L, Wenzel J, Moseley MK, Gaiha-Rohrbach J, Reynolds TL, Barbey C, Grogan JL, Colonna M.   +8 more
europepmc   +1 more source

Acute Myeloid Leukemia With Plasmacytoid Differentiating Cutaneous Lesions: A Case of Double Identity or Active Transformation. [PDF]

EJHaem
Lee BJ, Griffin SP, Jeyakumar D, Gamayo A, Rezk SA, Naqvi K.   +5 more
europepmc   +1 more source

Exploring current evidence on bispecific CAR-T cell therapy for acute leukemias: a systematic review. [PDF]

Front Oncol
Husodho GVP, Kumalasari ADA, Faiza AH, Limijadi EKS, Hendrianingtyas M.   +4 more
europepmc   +1 more source

Efficacy and safety of mini-cvd combined with venetoclax and azacitidine in philadelphia chromosome-negative acute leukemia of ambiguous lineage: a single-center retrospective study. [PDF]

Ann Hematol
Li Y, Shang Y, Liu K, Liu Y, Lin D, He J, Li J, Zeng Y, Wei H, Yan Z, Mi Y.   +10 more
europepmc   +1 more source

CD123 Is Consistently Expressed on NPM1-Mutated AML Cells [PDF]

Cancers, 2021
NPM1-mutated (NPM1mut) acute myeloid leukemia (AML) comprises about 30% of newly diagnosed AML in adults. Despite notable advances in the treatment of this frequent AML subtype, about 50% of NPM1mut AML patients treated with conventional treatment die due to disease progression.
Francesca Milano, Maria Paola Martelli, Alessandro Rambaldi   +2 more
exaly   +6 more sources

Some of the next articles are maybe not open access.

Related searches:

Targeting CD123 in BPDCN: an emerging field

Expert Review of Hematology, 2021
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy with historically poor outcomes for patients, often refractory to traditional chemotherapy. Recent research has focused on targeted therapy to improve responses and limit potential toxicity.CD123 (also known as IL-3 Rα) is a cell surface marker and ...
Naveen Pemmaraju, Adam Dipippo, Nathaniel Wilson   +2 more
exaly   +3 more sources

CD123 as a Biomarker in Hematolymphoid Malignancies: Principles of Detection and Targeted Therapies [PDF]

Cancers, 2020
CD123, the α chain of the interleukin 3 receptor, is a cytokine receptor that is overexpressed in multiple hematolymphoid neoplasms, including acute myeloid leukemia, blastic plasmacytoid dendritic cell neoplasm, acute lymphoblastic leukemia, hairy
Shilpa Paul, Hanadi El Achi, Joseph Khoury   +2 more
exaly   +2 more sources

The Expressions of CD30 and CD123 of Mastocytosis in Taiwan

Applied Immunohistochemistry & Molecular Morphology, 2021
Mastocytosis is a rare disease with a low incidence in Asia-Pacific populations. CD30 and CD123 may have potential prognostic and therapeutic value, but the results are inconsistent. Because racial disparities may exist, we aim to evaluate the expressions of CD30 and CD123 in a series of mastocytosis cases in Taiwan. Twelve patients with systemic and 7
Ching-Fen, Yang, Chih-Yi, Hsu
openaire   +2 more sources

CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotyping

Cytometry Part B - Clinical Cytometry, 2019
Background: While it is known that CD123 is normally strongly expressed on plasmacytoid dendritic cells and completely absent on nucleated red blood cells, detailed information regarding CD123 expression in acute leukemia is scarce and, if available ...
A E Bras, Vincent van der Velden
exaly   +1 more source

CD123 and its potential clinical application in leukemias

Life Sciences, 2015
The α chain of interleukin 3 receptor (IL-3Rα or CD123), together with the common β (βc) subunit, forms a high-affinity IL-3R with biological function. In recent years, emerging research has found that CD123 is highly expressed on the surface of various cells (e.g., leukemia stem cells, LSCs), and it is associated with the initiation and development of
Yechen Xiao, Yao Huang
exaly   +3 more sources